Ciprofloxacin hydrochloride

LNCaP, 786-0, ACHN and HT1376 cells were obtained from ATCC (Manassas, VA) and were maintained as recommended. C4-2 cells were obtained from Johns Isaacs (Johns Hopkins University, Baltimore, MD) and maintained in RPMI-1640. DPL-S11 cells were maintained in DMEM as previously described [44 (link)]. LMD cells are a derivative of MDA-MB-231 cells and were provided by Sridhar Nimmagadda (Johns Hopkins University, Baltimore, MD). LNCaP-MLuc are stable LNCaP cells derived to express the hMLuc reporter through the hβ-Actin promoter and enhancer; these cells are maintained under blasticidin selection as previously described [45 (link)]. All media contained 10 μg/mL ciprofloxacin hydrochloride (U.S. Biological, Swampscott, MA) and 10% fetal bovine serum.

LNCaP and C4-2 cells were obtained from the American Type Tissue Collection (ATCC) (Rockville, MD). Cells were grown in RPMI 1640 media (Corning, Manassas, VA) containing either 10% fetal bovine serum (Gemini Bio-Products, West Sacramento, CA) or 10% charcoal stripped fetal bovine serum (HyClone, Logan, UT and Sigma, St. Louis, MO) and supplemented with Ciprofloxacin Hydrochloride 5μg/ml (US Biological, Swampscott, MA), and Gentamicin 50 μg/ml (Quality Biological Inc., Gaithersburg, MD). The cells were passaged in uncoated filter top polystyrene flasks (Corning) and were maintained at 37°C in 5% CO₂ in humidified air. Cells were typically split at 80% confluency using 0.05% trypsin (cat # 25-052-CI; Corning) in calcium-free Hank's Buffered Salt Solution (Corning).